Information for site staff
Every COVID-19 patient in the UK may be invited to participate in the RECOVERY Trial. Randomisation includes the following arms: usual care alone; convalescent plasma; REGN-COV2 monoclonal antibodies; aspirin and colchicine. There is a second randomisation for participants who deteriorate between tocilizumab and control. The trial is designed to have the least possible impact on NHS staff. You will find Frequently Asked Questions on the site set-up page.
See Update Alert on this page for update details.
15 January 2021
This letter was sent to all principal investigators from the trial chief investigators following yesterday's Data Monitoring Committee. The DMC have recommended that no further participants are recruited to the convalescent plasma arm. All other arms of the trial continue unchanged.
The RECOVERY Trial protocol is available for use by investigators everywhere to design their own randomised trials that could help identify effective treatments for COVID-19.